02073nam a2200361Ia 4500001001200000003000600012005001700018007001400035008004100049040006300090043001200153074001900165088009000184086002300274110012000297245026100417260011400678300004500792336002600837337002700863338003100890504004100921500002600962500003600988500002501024533009401049610005301143650002401196650003501220650005001255776019501305776021101500ocm52167551OCoLC20180312141842.0he bmb024bbca030502s2002    dcua    bb   f000 0 eng d  aFPSbengcFPSdOCLCQdFCMBLdOCLCQdOCLCOdOCLCQdGPOdMvI  an-us---  a1019-B-01 (MF)  aSerial no. 107-142 (United States. Congress. House. Committee on Energy and Commerce)0 aY 4.C 73/8:107-1421 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Oversight and Investigations.13aAn inquiry into the ImClone cancer-drug story :bhearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002.  aWashington :bU.S. G.P.O. :bFor sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office],c2002.  aiii, 759 pages :billustrations ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  aIncludes bibliographical references.  a"Serial no. 107-142."  aShipping list no.: 2003-0183-M.  aCRDP Program record.  aMicrofiche.bWashington :cSupt. of Docs., U.S. G.P.O.,d2003.e9 microfiches : negative.20aImClone Systems IncorporatedxCorrupt practices. 0aCetuximabxTesting. 0aDrugszUnited StatesxTesting. 0aInsider trading in securitieszUnited States.08iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.tInquiry into the ImClone cancer-drug storyw(OCoLC)85278418108iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.tInquiry into the ImClone cancer-drug storyw(DLC) 2003426647w(OCoLC)51586262